10x Genomics 2025 Q3 Earnings Beats Revenue Estimates, Narrows Losses

Saturday, Nov 8, 2025 4:37 pm ET1min read
TXG--
Aime RobotAime Summary

- 10x Genomics (TXG) reported $149M Q3 revenue, exceeding Zacks' estimates by 4.64% while narrowing its net loss.

- Strong consumables sales offset 1.7% YoY revenue decline, with services revenue rising to $8.13M.

- Improved earnings and $1.2B cash reserves demonstrate resilience amid sector challenges and cost optimization progress.

- Post-earnings stock rally reflects investor confidence in automation-compatible FlexFLEX-- assay's long-term growth potential.

- CEO acknowledged macroeconomic headwinds but emphasized strategic focus on single-cell analysis technology leadership.

10x Genomics (TXG) delivered mixed results in Q3 2025, surpassing revenue expectations while narrowing its net loss. The company reported $149 million in revenue, a 4.64% beat over Zacks’ consensus, and guided for 5% sequential growth in Q4. Despite a year-over-year revenue decline, the improved earnings and robust cash position underscore resilience amid sector headwinds.

Revenue

, , respectively. Consumables remained a stronghold, . Services revenue rose to $8.13 million, . The decline in total revenue (-1.7% YoY) reflected softer instrument demand but was offset by strong consumables performance.

Earnings/Net Income

, . While the loss remains a concern, the reduction signals progress in cost management and operational efficiency.

Post-Earnings Price Action Review

, reflecting renewed investor confidence. . , including the automation-compatible Flex assay, position the company to capitalize on long-term demand for single-cell analysis. However, . , .

CEO Commentary

, . While acknowledging macroeconomic challenges, . .

Guidance

, . . , , .

Additional News

, . , , . . Additionally, , , has gained traction, .

Get noticed about the list of notable companies` earning reports after markets close today and before markets open tomorrow.

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet